Mosquito-Borne Infections Testing Market Size, Share & Trends Analysis Report By Application (Disease Surveillance, Clinical Diagnostics, Public Health Screening, Vaccine Development, Research & Epidemiology, Veterinary Testing), By Test Type (Rapid Diagnostic Tests, Molecular Tests, Serological Tests, Antigen Detection Tests, Immunofluorescence Assays), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Public Health Agencies, Research Institutions, Community Health Centers), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Mosquito-Borne Infections Testing Market Size & Growth Analysis

The global mosquito-borne infections testing market size was valued at USD 2.8 billion in 2025 and is projected to grow from USD 3.00 billion in 2026 to USD 5.15 billion by 2034, registering a CAGR of 7% during the forecast period from 2026 to 2034. Asia Pacific dominated the mosquito-borne infections testing market with a market share of 40% in 2025.

Market Segmentation

Test Type Insights

Rapid diagnostic tests (RDTs) represent the leading segment. They are widely used due to their portability, low cost (USD 5–10 per test), and ability to provide results in under 30 minutes. These tests are essential in outbreak settings, particularly in regions with limited laboratory capacity. RDTs, such as NS1 antigen assays, demonstrate high sensitivity (about 95%), allowing for early case detection and reducing onward transmission by an estimated 20%. Their adoption is strongest in endemic regions of Africa and Asia, where large populations rely on point-of-care diagnostics.

Request Customizationto receive a tailored report.

End-User Insights

Hospitals and clinics hold the largest market share. These facilities manage high patient volumes and are equipped to conduct confirmatory testing for infections such as dengue, Zika, and chikungunya. Molecular and serological platforms, such as Roche’s cobas analysers, enable high-throughput testing, processing up to 1,000 samples daily. The rise of urban outbreaks linked to Aedes mosquito expansion has further increased the demand for multiplex assays that can detect co-infections. Trained laboratory staff and integrated workflows support this segment’s growth, ensuring accurate results during seasonal and travel-associated outbreaks.

Technology Insights

Molecular diagnostics, particularly reverse transcription polymerase chain reaction (RT-PCR), lead the market. These tests achieve about 98% accuracy, detecting even low viral loads. RT-PCR is valuable for differential diagnosis in cases of co-infection and can simultaneously identify multiple pathogens. Expanding investment in PCR capacity also creates ongoing demand for reagents, making it a high-value segment for suppliers. National programmes and international donors increasingly prioritise PCR platforms to enhance surveillance and improve early outbreak detection.

Speak to an Analystto discuss market opportunities.

Asia Pacific: Dominant Region with 40% Market Share

Asia Pacific is the largest volume region due to endemic transmission in South East Asia, South Asia, parts of the Western Pacific, and frequent seasonal and large outbreaks. Governments in India, China and Southeast Asian countries routinely allocate RDTs and laboratory kits through national programmes. The region’s dual demand geometry from rural/POC need for RDTs and urban reference-lab demand for PCR/NGS drives a mixed market where global vendors coexist with strong local manufacturers like J Mitra in India, SD Biosensor in Korea, etc. For suppliers, Asia Pacific represents both the highest unit volumes in rapid tests and a growing high-value lab business as governments invest in molecular and genomic surveillance infrastructure.

China Market Trends

China is expanding its mosquito-borne infections testing market by combining community-based rapid testing with advanced molecular laboratories in major cities. The Chinese CDC has strengthened surveillance following dengue outbreaks in southern provinces, while hospitals in urban areas are adopting PCR and sequencing for accurate detection. The government supports local diagnostic kit manufacturing to reduce reliance on imports, which makes tests more affordable and widely available. China is a key dual-market for low-cost RDTs and higher-value molecular platforms.

Unlock Regional Insightsto access country-level data, & regional trends.

Latin America: Fastest-Growing Region with Significant Market Share

Latin America exhibits the fastest growth in the mosquito-borne infections testing market, with an 8.2% CAGR, driven by surging dengue and Zika cases, with Brazil reporting 6 million dengue cases in 2024 as per the WHO. Urban sprawl and climate shifts expand mosquito ranges, boosting test demand in the region. Government focus on outbreak preparedness and WHO-backed surveillance drives robust market expansion, addressing regional challenges like tourism-driven disease spread and making Latin America the fastest-growing region for diagnostic testing.

Countries Insights

U.s. Market Trends

The U.S. market is shaped by advanced diagnostic infrastructure and regulatory oversight. While most mosquito-borne cases are travel-related, locally acquired dengue in Florida, California, and Texas in 2024–2025 increased testing demand. The CDC expanded guidance for public health labs, recommending multiplex PCR assays to improve outbreak monitoring. Hospitals and reference labs rely on automated systems like Roche’s cobas for high-throughput testing, while clinics use NS1/IgM rapid tests for initial screening. Federal investment in genomic surveillance has further strengthened the detection of emerging pathogens such as Zika and West Nile virus.

Canada Market Growth Factors

Canada’s testing market is smaller in volume but highly regulated and focused on accuracy. Most mosquito-borne infections are travel-related, with screening concentrated in provincial public health labs and hospital systems. In 2025, the Public Health Agency of Canada and CATMAT linked diagnostics to dengue vaccination guidance, raising demand for reliable serological tests to confirm past exposure. Provincial labs such as Public Health Ontario maintain centralised PCR and ELISA testing, ensuring consistent results across regions.

Indonesia Market Growth Factors

Indonesia faces a high burden of mosquito-borne diseases, particularly dengue, with millions of cases reported each year. The government has prioritised diagnostic expansion as part of its national vector control programme. Rapid diagnostic tests remain critical in community health centres, while urban hospitals rely on PCR for confirmatory testing and co-infection detection. International donors, including WHO and the World Mosquito Program, also support surveillance upgrades, reinforcing Indonesia’s role as a key testing market in Southeast Asia.

Brazil Market Trends

Brazil is the largest testing market in Latin America, driven by recurring dengue outbreaks. In 2024, the country reported more than six million dengue cases, creating urgent demand for rapid testing. Urban hospitals increasingly use PCR platforms for confirmatory diagnostics, while RDTs remain essential in community health centres. Government partnerships with international donors and local manufacturers have helped distribute affordable kits widely. Brazil continues to scale up both rapid and advanced diagnostics to control outbreaks effectively.

Competitive Landscape

The global market is highly fragmented and dominated by companies offering diverse diagnostics like PCR and RDTs, with strong R&D in multiplex and POC solutions to address outbreaks. Players leverage partnerships with health agencies for global distribution, focusing on affordability in emerging markets and innovation for high specificity, driving share through regulatory approvals and scalability amid climate-driven demands.

Roche Diagnostics: An Emerging Player

Roche Diagnostics pursues a platform-led strategy. Their automated immunoassay menus (Elecsys) and high-throughput molecular systems (cobas 6800/8800) sell instruments and recurring reagents to reference labs and national programmes. During the 2024–2025 dengue response, Roche emphasised expanded dengue assay coverage (antigen/Ig panels) and multiplex molecular workflows, aligning with WHO guidance for confirmation and surveillance.

Latest news:

• In May 2025, Roche included Elecsys Dengue Ag and expanded infectious-disease assay messaging in its Diagnostics Day material, signalling product-menu expansion for automated antigen testing and integrated lab workflows.

List of Key and Emerging Players in Mosquito-Borne Infections Testing Market